Search
NEWS

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

By A Mystery Man Writer

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

Fibrosis In Vivo Disease Models - Aragen Life Sciences

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

Adiponectin-derived active peptide ADP355 exerts anti-inflammatory

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

CD352 (NTB-A) Antibody, anti-human, REAfinity™

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

CD352 (NTB-A) Antibody, anti-human, REAfinity™

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

Comparing species-different responses in pulmonary fibrosis

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

In vivo production of CAR-T cells using CD5/LNP-FAPCAR

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

Fibroblast activation protein activated antifibrotic peptide